Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates
Anebulo Reports Second Quarter Fiscal Year 2024 Financial Results
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results
Anebulo Pharmaceuticals Announces New CEO
Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse (the “Company” or “Anebulo”), today announced that it will be giving an investor presentation at the H.C. Wainwright 25th Annual Global Investment Conference, from September 11 to September 13. In addition, the Company announced the acceptance of three presentations at two upcoming scientific conferences, the North American Congress on Clinical Toxicology, taking place in Montreal, from September 29 to October 1, and the American Congress of Emergency Physicians, taking place in Philadelphia from October 9 to October 12. The two oral presentations will focus on data from Parts A and B of the Phase 2 study and the poster will present modeling of ANEB-001 doses for ACI.
Anebulo Receives Positive Feedback from FDA on Path to Advance Phase 3 Clinical Development of ANEB-001 and Completes Dosing of Phase 2 Extension